Pucotenlimab

普特利单抗

Report date: 2026/04/22 20:01:10

Base Information

Drug NamePucotenlimab
Drug Alias NamePutalimabptemizumabPutlimumab普佑恒Puyouheng +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursMicrosatellite instability-high cancer +[18] 
Global Approved IndicationsMicrosatellite instability-high cancerMismatch Repair Deficient Cancer
Approved Indications in ChinaMicrosatellite instability-high cancerMismatch Repair Deficient Cancer
Original Approved Country/TerritoryMainland China
Original Approved Date2022/07/19
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHanx Biopharmaceutical Co LtdZhongshan Akeso Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan Binhui Biotechnology Co LtdLepu Medical Technology (Beijing) Co LtdFujian Medical University +[10] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursMicrosatellite instability-high cancer +[17] 
Inactive IndicationsThyroid Carcinoma, Anaplastic

Other Information

ATC CodeN/A
Related LinksN/A